Patents Assigned to Antigenics Inc.
  • Publication number: 20120270232
    Abstract: The present invention relates, in general, to methods of screening a sample obtained from a subject for antibodies relating to granulocytic ehrlichia (GE) infection.
    Type: Application
    Filed: June 25, 2012
    Publication date: October 25, 2012
    Applicant: Antigenics Inc.
    Inventors: Cheryl Murphy, James Storey, Gerald A. Beltz, Richard T. Coughlin
  • Publication number: 20120178102
    Abstract: The present invention relates, in general, to granulocytic ehrlichia (GE) proteins. In particular, the present invention relates to nucleic acid molecules coding for GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins; purified GE S2, S7, S22, S23, C6.1, C6.2, S1, E8, E46#1, and E46#2 proteins and polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to GE S2, S7, S22, S23, C6.1, C6.2, S1, E8, E46#1, and E46#2 proteins and polypeptides; hybridomas containing the antibodies; nucleic acid probes for the detection of nucleic acids encoding GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins; a method of detecting nucleic acids encoding GE S2, S7, S22, S23, C6.1, C6.
    Type: Application
    Filed: January 9, 2012
    Publication date: July 12, 2012
    Applicant: Antigenics Inc.
    Inventors: Cheryl Murphy, James Storey, Gerald A. Beltz, Richard T. Coughlin
  • Patent number: 7863434
    Abstract: The present invention relates, in general, to granulocytic ehrlichia (GE) proteins. In particular, the present invention relates to nucleic acid molecules coding for GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins; purified GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins and polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins and polypeptides; hybridomas containing the antibodies; nucleic acid probes for the detection of nucleic acids encoding GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins; a method of detecting nucleic acids encoding GE S2, S7, S22, S23, C6.1, C6.
    Type: Grant
    Filed: February 26, 2001
    Date of Patent: January 4, 2011
    Assignee: Antigenics Inc.
    Inventors: Cheryl Murphy, James Storey, Gerald A. Beltz, Richard T. Coughlin
  • Patent number: 7858589
    Abstract: Vaccine compositions of immunostimulatory oligonucleotides and saponin adjuvants and antigens and the use thereof for stimulating immunity, enhancing cell-mediated immunity, and enhancing antibody production are disclosed. Also described are immune adjuvant compositions comprising immunostimulatory oligonucleotides and saponin adjuvants, as well as methods for increasing an immune response using the same.
    Type: Grant
    Filed: March 10, 2006
    Date of Patent: December 28, 2010
    Assignee: Antigenics Inc.
    Inventor: Charlotte A. Kensil
  • Patent number: 7420037
    Abstract: Hybrid antigens comprising an antigenic domain and improved heat shock protein binding domains are described which are useful for the induction of an immune response to the antigenic domain and thus can be used to treat infectious diseases and cancers that express an antigen of the antigenic domain.
    Type: Grant
    Filed: February 12, 2004
    Date of Patent: September 2, 2008
    Assignee: Antigenics Inc.
    Inventors: Paul Slusarewicz, Sunil Mehta
  • Patent number: 7309491
    Abstract: Hybrid antigens comprising at least one antigenic domain, at least one heat shock protein binding domain, and at least one improved peptide linker there between are described which are useful for the induction of an immune response to the antigenic domain when administered alone or in a complex with at least one heat shock protein. The hybrid antigens and complexes can be used to treat infectious diseases and cancers that express an antigen of the antigenic domain.
    Type: Grant
    Filed: April 8, 2004
    Date of Patent: December 18, 2007
    Assignee: Antigenics Inc.
    Inventors: Paul Slusarewicz, Jessica Baker Flechtner, Sunil Mehta, Kenya Prince-Cohane, Sofija Andjelic, Brian H. Barber
  • Patent number: 7049302
    Abstract: Vaccine compositions of immunostimulatory oligonucleotides and saponin adjuvants and antigens and the use thereof for stimulating immunity, enhancing cell-mediated immunity, and enhancing antibody production are disclosed. Also described are immune adjuvant compositions comprising immunostimulatory oligonucleotides and saponin adjuvants, as well as methods for increasing an immune response using the same.
    Type: Grant
    Filed: August 6, 1999
    Date of Patent: May 23, 2006
    Assignee: Antigenics Inc.
    Inventor: Charlotte A. Kensil
  • Patent number: 7030094
    Abstract: The invention provides pharmaceutical compositions, particularly vaccine compositions, employing an adjuvant system comprising RC-529 (an aminoalkyl glucosaminide phosphate compound) and QS-21 (a saponin). Such compositions synergistically enhance the immune response in a mammal to a co-administered antigen. Also provided are methods of using the compositions in the treatment of various human diseases, including cancer, microbial infections and autoimmune disorders.
    Type: Grant
    Filed: June 21, 2002
    Date of Patent: April 18, 2006
    Assignees: Corixa Corporation, Antigenics Inc.
    Inventors: Sally Mossman, Lawrence Evans
  • Publication number: 20040258705
    Abstract: The present invention relates to using lectin or lectin-like molecules to promote oligomerization of a glycoprotein or an immunologically and/or biologically active complex comprising glycoproteins. In particular, the invention provides compositions of a molecular complex comprising lectin molecules and immunologically and/or biologically active molecules. Methods of making such molecular complexes and methods of use of the compositions comprising such molecular complexes for the prevention and treatment of diseases, particularly cancer and infectious diseases, and for eliciting an immune response in a subject, are also provided.
    Type: Application
    Filed: February 27, 2004
    Publication date: December 23, 2004
    Applicant: Antigenics Inc.
    Inventors: James R. Zabrecky, Stephen A. Monks